Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Rockwell Medical management to virtually meet with Cantor Fitzgerald » 04:55
06/30/20
06/30
04:55
06/30/20
04:55
RMTI

Rockwell Medical

$1.93 /

+0.125 (+6.93%)

Two Days of Virtual…

Two Days of Virtual Meetings with Management, June 29-June 30. For more information, please call your representative or Investor Relations at 248-960-9009.

ShowHide Related Items >><<
RMTI Rockwell Medical
$1.93 /

+0.125 (+6.93%)

RMTI Rockwell Medical
$1.93 /

+0.125 (+6.93%)

03/27/20 Piper Sandler
Piper Sandler remains buyer of Rockwell Medical after Triferic AVNU approval
02/27/20 Piper Sandler
Piper says Rockwell's triferic update 'encouraging' but 'anti-climactic'
11/11/19 Piper Sandler
Rockwell Medical price target lowered to $6 from $10 at Piper Jaffray
07/30/19 Piper Sandler
Piper Jaffray says proposed TDAPA change a curveball, still bullish on Rockwell
RMTI Rockwell Medical
$1.93 /

+0.125 (+6.93%)

  • 04
    Feb
RMTI Rockwell Medical
$1.93 /

+0.125 (+6.93%)

Monday
Conference/Events
Rockwell Medical management to virtually meet with Cantor Fitzgerald » 12:18
06/29/20
06/29
12:18
06/29/20
12:18
RMTI

Rockwell Medical

$1.88 /

+0.075 (+4.16%)

Two Days of Virtual…

Two Days of Virtual Meetings with Management, June 29-June 30. For more information, please call your representative or Investor Relations at 248-960-9009.

ShowHide Related Items >><<
RMTI Rockwell Medical
$1.88 /

+0.075 (+4.16%)

RMTI Rockwell Medical
$1.88 /

+0.075 (+4.16%)

03/27/20 Piper Sandler
Piper Sandler remains buyer of Rockwell Medical after Triferic AVNU approval
02/27/20 Piper Sandler
Piper says Rockwell's triferic update 'encouraging' but 'anti-climactic'
11/11/19 Piper Sandler
Rockwell Medical price target lowered to $6 from $10 at Piper Jaffray
07/30/19 Piper Sandler
Piper Jaffray says proposed TDAPA change a curveball, still bullish on Rockwell
RMTI Rockwell Medical
$1.88 /

+0.075 (+4.16%)

  • 04
    Feb
RMTI Rockwell Medical
$1.88 /

+0.075 (+4.16%)

Over a week ago
Hot Stocks
Affimed N.V. names Angus Smith as CFO » 06:33
06/11/20
06/11
06:33
06/11/20
06:33
AFMD

Affimed N.V.

$3.24 /

-0.07 (-2.11%)

, RMTI

Rockwell Medical

$2.13 /

-0.01 (-0.47%)

Affimed N.V. (AFMD)…

Affimed N.V. (AFMD) announced the appointment of Angus Smith as CFO, completing Affimed's leadership team. Smith will begin his employment on July 13 and will be based out of Affimed's New York office. Smith has broad biopharmaceutical industry experience including financial strategy, capital markets, business development and operations. He joins Affimed from Rockwell Medical (RMTI) where he served as CFO.

ShowHide Related Items >><<
RMTI Rockwell Medical
$2.13 /

-0.01 (-0.47%)

AFMD Affimed N.V.
$3.24 /

-0.07 (-2.11%)

AFMD Affimed N.V.
$3.24 /

-0.07 (-2.11%)

RMTI Rockwell Medical
$2.13 /

-0.01 (-0.47%)

03/27/20 Piper Sandler
Piper Sandler remains buyer of Rockwell Medical after Triferic AVNU approval
02/27/20 Piper Sandler
Piper says Rockwell's triferic update 'encouraging' but 'anti-climactic'
11/11/19 Piper Sandler
Rockwell Medical price target lowered to $6 from $10 at Piper Jaffray
07/30/19 Piper Sandler
Piper Jaffray says proposed TDAPA change a curveball, still bullish on Rockwell
RMTI Rockwell Medical
$2.13 /

-0.01 (-0.47%)

RMTI Rockwell Medical
$2.13 /

-0.01 (-0.47%)

AFMD Affimed N.V.
$3.24 /

-0.07 (-2.11%)

Over a month ago
Hot Stocks
Rockwell Medical files NDS with Health Canada for approval of Triferic AVNU » 07:04
05/26/20
05/26
07:04
05/26/20
07:04
RMTI

Rockwell Medical

$2.12 /

+0.02 (+0.95%)

Rockwell Medical…

Rockwell Medical announced the filing of a New Drug Submission with Health Canada for Triferic AVNU. The Company seeks an indication to promote Triferic AVNU in Canada for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. The filing is the first international regulatory submission for the intravenous therapy. Rockwell Medical has a distribution agreement with RMC Canada, through which Rockwell Medical will receive a transfer price based on Triferic sales in Canada, subject to Canadian regulatory approval.

ShowHide Related Items >><<
RMTI Rockwell Medical
$2.12 /

+0.02 (+0.95%)

RMTI Rockwell Medical
$2.12 /

+0.02 (+0.95%)

03/27/20 Piper Sandler
Piper Sandler remains buyer of Rockwell Medical after Triferic AVNU approval
02/27/20 Piper Sandler
Piper says Rockwell's triferic update 'encouraging' but 'anti-climactic'
11/11/19 Piper Sandler
Rockwell Medical price target lowered to $6 from $10 at Piper Jaffray
07/30/19 Piper Sandler
Piper Jaffray says proposed TDAPA change a curveball, still bullish on Rockwell
RMTI Rockwell Medical
$2.12 /

+0.02 (+0.95%)

RMTI Rockwell Medical
$2.12 /

+0.02 (+0.95%)

Earnings
Rockwell Medical reports Q1 EPS (12c), consensus (12c) » 17:26
05/11/20
05/11
17:26
05/11/20
17:26
RMTI

Rockwell Medical

$2.46 /

+0.12 (+5.13%)

Reports Q1 revenue…

Reports Q1 revenue $15.9M, consensus $15.8M. "In my new role, my charge is to maximize the commercial potential of our two FDA-approved products, Triferic Dialysate and Triferic AVNU, while developing Rockwell Medical into a more medically- and scientifically-driven company, which includes leading the strategic identification and pursuit of new therapeutic areas for our ferric pyrophosphate citrate platform," said Russell Ellison, M.D., M.Sc., President and Chief Executive Officer of Rockwell Medical. "I am pleased to report continued progress in our commercialization of Triferic Dialysate in the first quarter, including an acceleration of Triferic Dialysate Evaluation Programs and a continued increase in contracted clinics. Importantly, we secured FDA approval of Triferic AVNU at the end of March and are working diligently to prepare for a successful launch of this intravenous ("IV") formulation later this year." Dr. Ellison added: "In addition, we are encouraged by the top-line data announced today from a retrospective real-world analysis of Triferic Dialysate within a dialysis clinic. Following adoption of Triferic within the studied clinic, we observed the reduction of the use of erythropoietin stimulating agents ("ESAs") and traditional IV iron, improvement in hemoglobin levels, fewer missed appointments among patients, and an improvement in patients' quality of life. These measures are important factors in patient care and speak to the value that Triferic can confer to providers, patients and the overall healthcare system."

ShowHide Related Items >><<
RMTI Rockwell Medical
$2.46 /

+0.12 (+5.13%)

03/27/20 Piper Sandler
Piper Sandler remains buyer of Rockwell Medical after Triferic AVNU approval
02/27/20 Piper Sandler
Piper says Rockwell's triferic update 'encouraging' but 'anti-climactic'
11/11/19 Piper Sandler
Rockwell Medical price target lowered to $6 from $10 at Piper Jaffray
07/30/19 Piper Sandler
Piper Jaffray says proposed TDAPA change a curveball, still bullish on Rockwell
Hot Stocks
Rockwell Medical appoints Russell Ellison as president, CEO » 08:32
04/20/20
04/20
08:32
04/20/20
08:32
RMTI

Rockwell Medical

$2.45 /

+0.045 (+1.88%)

Rockwell Medical…

Rockwell Medical announced that the Board of Directors has appointed Russell Ellison, M.D., M.Sc. as President and CEO, effective immediately. Ellison will continue to serve as a member of the Company's Board. Stuart Paul has resigned as President and CEO and as a member of the Company's Board of Directors. Ellison's broad experience and previous leadership positions include CEO of the privately held biotechnology company, Promedior; President and CEO of Bond Biosciences, Inc., a biotech start-up developing a drug addressing the toxic impact of iron overload in the body; Executive Director of Torreya Advisors, LLC, a life sciences investment banking firm.

ShowHide Related Items >><<
RMTI Rockwell Medical
$2.45 /

+0.045 (+1.88%)

03/27/20 Piper Sandler
Piper Sandler remains buyer of Rockwell Medical after Triferic AVNU approval
02/27/20 Piper Sandler
Piper says Rockwell's triferic update 'encouraging' but 'anti-climactic'
11/11/19 Piper Sandler
Rockwell Medical price target lowered to $6 from $10 at Piper Jaffray
07/30/19 Piper Sandler
Piper Jaffray says proposed TDAPA change a curveball, still bullish on Rockwell
Over a quarter ago
Recommendations
Piper Sandler remains buyer of Rockwell Medical after Triferic AVNU approval » 13:51
03/27/20
03/27
13:51
03/27/20
13:51
RMTI

Rockwell Medical

$2.28 /

-0.14 (-5.79%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond noted that the FDA approved Rockwell Medical's Triferic AVNU, the intravenously-administered formulation of Triferic, as he expected. While he doesn't expect the IV revenue contribution to begin near-term, he expects Triferic IV to make up greater than 70% of U.S. Triferic revenue by 2025, so this approval was key to his thesis, Raymond tells investors. The analyst, who would remain a buyer of the shares, keeps an Overweight rating on Rockwell.

ShowHide Related Items >><<
RMTI Rockwell Medical
$2.28 /

-0.14 (-5.79%)

02/27/20 Piper Sandler
Piper says Rockwell's triferic update 'encouraging' but 'anti-climactic'
11/11/19 Piper Sandler
Rockwell Medical price target lowered to $6 from $10 at Piper Jaffray
07/30/19 Piper Sandler
Piper Jaffray says proposed TDAPA change a curveball, still bullish on Rockwell
06/25/19
Fly Intel: Top five analyst initiations
Hot Stocks
Rockwell Medical receives FDA approval for Triferic AVNU » 11:24
03/27/20
03/27
11:24
03/27/20
11:24
RMTI

Rockwell Medical

$2.43 /

+0.01 (+0.41%)

Rockwell Medical…

Rockwell Medical announced that the U.S. Food and Drug Administration has approved its New Drug Application for its intravenous formulation of Triferic, Triferic AVNU. With this approval, Triferic AVNU joins Triferic Dialysate as the only FDA-approved products indicated to replace iron and maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Triferic is a novel, physiologic iron maintenance therapy that provides bioavailable iron to replace iron lost during every dialysis treatment and maintain hemoglobin. While Triferic Dialysate is designed to be administered via liquid bicarbonate, Triferic AVNU is designed for direct intravenous infusion, which provides hemodialysis patients with greater access to the Triferic platform and expands administration options for clinicians. Triferic AVNU can be administered regardless of a dialysis center's mode of bicarbonate delivery. Many dialysis centers in international markets and an increasing number of dialysis centers in the U.S. have converted to the use of dry bicarbonate cartridges or bags and on-line dialysate generation, which is not compatible with Triferic Dialysate. Over the next several months, the Company plans to initiate a commercial strategy that leverages the experience gained from the 2019 launch of Triferic Dialysate and lays the groundwork for the commercial introduction of Triferic AVNU. The Company expects to launch Evaluation Programs during the third quarter of 2020 to allow clinics to gain direct experience with Triferic AVNU, and the Company expects Triferic AVNU to be available commercially following the completion of the initial Evaluation Programs.

ShowHide Related Items >><<
RMTI Rockwell Medical
$2.43 /

+0.01 (+0.41%)

02/27/20 Piper Sandler
Piper says Rockwell's triferic update 'encouraging' but 'anti-climactic'
11/11/19 Piper Sandler
Rockwell Medical price target lowered to $6 from $10 at Piper Jaffray
07/30/19 Piper Sandler
Piper Jaffray says proposed TDAPA change a curveball, still bullish on Rockwell
06/25/19
Fly Intel: Top five analyst initiations
Hot Stocks
Rockwell Medical confirms MRAG's director nominations are invalid » 08:35
03/20/20
03/20
08:35
03/20/20
08:35
RMTI

Rockwell Medical

$2.21 /

+0.335 (+17.91%)

Rockwell Medical…

Rockwell Medical reiterated that Medical Resource Acquisition Group failed to properly deliver a notice of director nominations under the Company's Bylaws within the prescribed advance notice period. The company said, "While MRAG has continued its attempts to confuse shareholders into believing otherwise, the Company has been abundantly clear in its communications with MRAG and its advisors that MRAG's three director nominees will not stand for election at the Company's 2020 annual meeting of stockholders. The Company will also make copies of such correspondence available on our website, URL The Company continues to advise shareholders to exercise caution in connection with this matter."

ShowHide Related Items >><<
RMTI Rockwell Medical
$2.21 /

+0.335 (+17.91%)

02/27/20 Piper Sandler
Piper says Rockwell's triferic update 'encouraging' but 'anti-climactic'
11/11/19 Piper Sandler
Rockwell Medical price target lowered to $6 from $10 at Piper Jaffray
07/30/19 Piper Sandler
Piper Jaffray says proposed TDAPA change a curveball, still bullish on Rockwell
06/25/19
Fly Intel: Top five analyst initiations
Hot Stocks
MRAG urgess Rockwell Medical shareholders to support director nominees » 08:47
03/16/20
03/16
08:47
03/16/20
08:47
RMTI

Rockwell Medical

$1.62 /

-0.475 (-22.67%)

Medical Resource…

Medical Resource Acquisition Group announces that it has been receiving support from Rockwell shareholders who are in favor of Rockwell Medical receiving $15M in funding and having three new Directors replace Directors Lisa Colleran, John Cooper and Mark Ravich. The company said, "In light of the tremendous support for MRAG a weblink has been set up on the MRAG website. We encourage all shareholders to place their support and be able to stay further informed by going to www.MRAGWORLD.COM and click ROCKWELL OFFERS. MRAG has proposed funding of $15 million, as well as new directors for Rockwell Medical Inc., in a bid to restructure and reinvigorate the company. Mr. Shroff believes that MRAG and its advisers can bring new opportunities to the company, both in terms of an expansion of its business interests and in terms of finance. Mr. Shroff believes that the funding offered by MRAG will empower Rockwell to make great strides into huge, new markets which lay beyond those currently being considered and serviced...A substantive effect of MRAG's offer of equity funding to RMTI, made on February 25, 2020, will be the introduction of appropriate healthcare innovations to the Middle and Far East market that target current needs and future projections...MRAG has nominated Mr. Khurram Shroff, Mr. Arthur S. Reynolds and Mr. Markus Muller for election as directors at the Rockwell annual shareholder meeting and believes that they have much more to offer Rockwell than the directors currently on the Board."

ShowHide Related Items >><<
RMTI Rockwell Medical
$1.62 /

-0.475 (-22.67%)

02/27/20 Piper Sandler
Piper says Rockwell's triferic update 'encouraging' but 'anti-climactic'
11/11/19 Piper Sandler
Rockwell Medical price target lowered to $6 from $10 at Piper Jaffray
07/30/19 Piper Sandler
Piper Jaffray says proposed TDAPA change a curveball, still bullish on Rockwell
06/25/19
Fly Intel: Top five analyst initiations

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.